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Developing and validating sensitive biomarkers for the presymptomatic stage of familial frontotemporal dementia is an important
step in early diagnosis and for the design of future therapeutic trials. In the longitudinal Frontotemporal Dementia Risk Cohort,
presymptomatic mutation carriers and non-carriers from families with familial frontotemporal dementia due to microtubule-
associated protein tau (MAPT) and progranulin (GRN) mutations underwent a clinical assessment and multimodal MRI at base-
line, 2-, and 4-year follow-up. Of the cohort of 73 participants, eight mutation carriers (three GRN, ﬁve MAPT) developed clinical
features of frontotemporal dementia (‘converters’). Longitudinal whole-brain measures of white matter integrity (fractional anisot-
ropy) and grey matter volume in these converters (n = 8) were compared with healthy mutation carriers (‘non-converters’; n = 35)
and non-carriers (n =30) from the same families. We also assessed the prognostic performance of decline within white matter and
grey matter regions of interest by means of receiver operating characteristic analyses followed by stepwise logistic regression.
Longitudinal whole-brain analyses demonstrated lower fractional anisotropy values in extensive white matter regions (genu corpus
callosum, forceps minor, uncinate fasciculus, and superior longitudinal fasciculus) and smaller grey matter volumes (prefrontal,
temporal, cingulate, and insular cortex) over time in converters, present from 2years before symptom onset. White matter integrity
loss of the right uncinate fasciculus and genu corpus callosum provided signiﬁcant classiﬁers between converters, non-converters,
and non-carriers. Converters’ within-individual disease trajectories showed a relatively gradual onset of clinical features in MAPT,
whereas GRN mutations had more rapid changes around symptom onset. MAPT converters showed more decline in the uncinate
fasciculus than GRN converters, and more decline in the genu corpus callosum in GRN than MAPT converters. Our study conﬁrms
the presence of spreading predominant frontotemporal pathology towards symptom onset and highlights the value of multimodal
MRI as a prognostic biomarker in familial frontotemporal dementia.
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Introduction
Frontotemporal dementia (FTD) is the second most
common presenile dementia disorder (onset 565 years),
with a clinical proﬁle of behavioural disturbances and/or
language deterioration [behavioural variant (bv)FTD or pri-
mary progressive aphasia (PPA)] (Agosta et al., 2012;
Rohrer and Rosen, 2013; Frings et al., 2014). FTD can
have an autosomal dominant inheritance pattern, with mu-
tations in the GRN or MAPT genes and the C9orf72 repeat
expansion as its three major causes (Warren et al., 2013).
Structural neuroimaging studies in symptomatic FTD
have shown predominant grey matter volume loss of
the prefrontal cortex, anterior temporal lobe, insula and
anterior cingulate cortex early in the disease course, with at-
rophy increasing as the disease progresses (Seeley et al.,
2008; Whitwell et al., 2009a, 2015; Piguet et al., 2011).
Studies now also suggest white matter integrity loss
as a hallmark of FTD, exceeding grey matter atrophy in
location and severity (Agosta et al., 2012; Rohrer and
Rosen, 2013; Frings et al., 2014; Lam et al., 2014).
The uncinate fasciculus, connecting the orbitofrontal
cortex, temporal pole, insula and amygdala, has been sug-
gested as the key target of network-led neurodegeneration
early in the disease process (Mahoney et al., 2014;
Oishi et al., 2015; see also the literature review in the
Supplementary material).
Comparable to studies in presymptomatic familial
Alzheimer’s (Bateman et al., 2012; Benzinger et al., 2013;
Kinnunen et al., 2018) and Huntington’s disease (Tabrizi
et al., 2013; Harrington et al., 2016), converging evidence
from studies in familial FTD also demonstrates the presence
of a presymptomatic stage, reﬂected in early changes in
neuroimaging, cognition, blood, and CSF (Borroni et al.,
2008; Dopper et al., 2014; Rohrer et al., 2015; Jiskoot
et al., 2016, 2018a, b; Meeter et al., 2016). White matter
integrity loss of the uncinate fasciculus was found in the
presymptomatic stage of both MAPT (Dopper et al., 2014;
Jiskoot et al., 2018b), and GRN mutation carriers (Borroni
et al., 2008). Studies demonstrated gene-speciﬁc white
matter integrity loss in the forceps minor in MAPT
(Dopper et al., 2014), and the inferior fronto-occipital fas-
ciculus (Borroni et al., 2008), and internal capsule (Jiskoot
et al., 2018b) in GRN. Grey matter volume loss was found
in, amongst others, the frontal, temporal, insular, and cin-
gulate cortices (Janssen et al., 2005; Cruchaga et al., 2009;
Rohrer et al., 2015). Cognitive and structural neuroimaging
changes were identiﬁed from 5 to 10 years before estimated
onset, respectively, with the ﬁrst changes in MAPT being
naming deﬁcits and grey matter volume loss of the tem-
poral lobe (hippocampus and amygdala), and the ﬁrst
changes in GRN being working memory deﬁcits and grey
matter volume loss of the insula (Rohrer et al., 2015).
Although these results suggest a pathophysiological cascade
of events in the presymptomatic stage of familial FTD, in-
terpretation of these changes is hampered by the fact that
analyses are based on cross-sectional data, and therefore do
not represent individual longitudinal trajectories (Bateman
et al., 2012; Schuster et al., 2015). Moreover, these studies
make use of estimated years to symptom onset as a proxy
for actual symptom onset, which is commonly used in fa-
milial Alzheimer’s disease (Bateman et al., 2012; Ryman
et al., 2014; Kinnunen et al., 2018). Estimated years to
onset is, however, far less accurate in familial FTD, given
the large variation in age at onset between and within
families (van Swieten and Heutink, 2008). Recent longitu-
dinal analyses on 4-year follow-up neuropsychological as-
sessment data (Jiskoot et al., 2018a) demonstrated subtle
cognitive decline, starting 2 years prior to the development
of clinical symptoms, suggesting a more sudden onset
rather than a gradual acceleration when approaching the
symptomatic disease stage. Longitudinal neuroimaging stu-
dies describing the trajectories of white matter integrity and
grey matter volume loss in the presymptomatic stage of
MAPT and GRN mutations are still lacking, but could
provide valuable information on (i) imaging-based disease
staging; (ii) characterization of disease trajectories; (iii) val-
idation of prognostic biomarkers; and (iv) establishing the
sensitivity of various neuroimaging techniques in early dis-
ease stages (Schuster et al., 2015).
In this study, we investigated longitudinal changes in grey
matter volume and white matter integrity over a 4-year
follow-up period in mutation carriers that developed clin-
ical features of FTD in this time window (converters),
presymptomatic mutation carriers (non-converters), and
non-carriers from Dutch FTD families with GRN or
MAPT mutations. The study aims are threefold: (i) to in-
vestigate cross-sectional and longitudinal changes in white
matter integrity and grey matter volume between con-
verters, non-converters and non-carriers from 4 years
before to symptom onset; (ii) to explore converters’
within-individual trajectories; and (iii) to determine the
prognostic value of longitudinal decline in multimodal neu-
roimaging parameters in predicting symptom onset, and to
establish the best combination of multimodal neuroimaging
parameters.
194 | BRAIN 2019: 142; 193–208 L. C. Jiskoot et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/193/5225004 by Erasm
us U
niversity R
otterdam
 user on 07 January 2019
Materials and methods
Participants
A cohort of 83 participants with 50% risk of developing familial
FTD, recruited between December 2009 and October 2012 from
large Dutch families with MAPT or GRN mutations (Dopper
et al., 2014, 2016; Jiskoot et al., 2016, 2018a), were followed on
a 2-year basis over a time period of 4 years. DNA genotyping
assigned participants either to the mutation carrier or non-carrier
group: 43 mutation carriers (30 GRN, 13 MAPT) and 40 non-
carriers (31 GRN family members, nine MAPT family members).
At study entry, participants were asymptomatic according to es-
tablished diagnostic criteria for bvFTD (Rascovsky et al., 2011)
or PPA (Gorno-Tempini et al., 2011), with FTD Clinical
Dementia Rating–sum of boxes (FTD-CDR-SB) scores of 0
(Knopman et al., 2008). The study selection of mutation carriers
was based on the presence of at least one follow-up MRI scan.
We excluded 10 non-carriers who had not undergone all three
study visits to ascertain stability of the data points, leaving 73
eligible participants in the ﬁnal dataset (Fig. 1).
Standard protocol approvals,
registrations, and patient consents
The clinical investigators and participants were blind for the
participants’ genetic status, except for those that underwent pre-
dictive testing at their own request. For converters, we offered
genetic counselling to the patient and family members, and we
unblinded the genetic status to conﬁrm the presence of the patho-
genic mutation. All participants gave written informed consent at
study entry. The study was approved by the Medical and Ethical
Review Committee of the Erasmus Medical Center.
Clinical assessment
Every 2years, all participants underwent a standardized clinical
assessment consisting of a brain MRI, medical history, neuro-
logical examination, and an extensive neuropsychological test
battery. Knowledgeable informants (e.g. siblings, spouses) were
asked about functional, cognitive, behavioural and/or neuro-
psychiatric changes by means of a structured interview, FTD-
CDR-SB (Knopman et al., 2008), and the Neuropsychiatric
Inventory (NPI-Q), a well-validated questionnaire for neuro-
psychiatric features (Kaufer et al., 2000), either during the
study visit or afterwards in a telephone interview. Participants’
depressive features were rated every study visit by means of the
BDI (Beck et al., 1961). Neuropsychological testing consisted of
screening tests for global cognition—the Mini-Mental State
Examination (MMSE; Folstein et al., 1975) and Frontal
Assessment Battery (FAB; Dubois and Litvan, 2000)—and tests
within the domains of language, attention and mental processing
speed, executive function, memory, visuoconstruction, and social
cognition (see Jiskoot et al., 2016, 2018a for the full battery).
Converters
Eight mutation carriers developed clinical features of FTD, ﬁve
carrying an MAPT mutation and three carrying a GRN mu-
tation. Using the information from the above-mentioned clinical
Figure 1 Study design. A schematic timeline of the 4-year follow-up of presymptomatic mutation carriers, converters and non-carriers within
FTD-RisC. Eight mutation carriers converted to clinical FTD within the study window; two between baseline and follow-up after 2 years, and six
between follow-up after 2 and 4 years. For the data analysis, the data were restructured into three new time points: 4 years before symptom
onset, 2 years before symptom onset, and symptom onset.
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assessment in a multidisciplinary consensus meeting of the
Erasmus MC FTD Expertise Centre, we deemed mutation car-
riers to be converters (either bvFTD or PPA) if they met the
following criteria: (i) progressive deterioration of behaviour and/
or language by observation or history (as provided by a know-
ledgeable informant); (ii) signiﬁcant functional decline (evi-
denced by FTD-CDR-SB scores 51 at the ﬁrst or second
follow-up visit); and (iii) cognitive deﬁcits [51 standard devi-
ation (SD) in at least one domain] on neuropsychological as-
sessment. The frontal and/or temporal atrophy on MRI in six
converters (ﬁve MAPT, one GRN), together with progressive
behaviour deterioration, functional decline, and cognitive def-
icits, met the international diagnostic consensus criteria (A–C)
for probable bvFTD (Rascovsky et al., 2011). The presence of
predominant left posterior fronto-insular atrophy on MRI in
two converters (both GRN), in combination with a non-
ﬂuent, halting speech, sound errors and agrammatism, impaired
comprehension of syntactically complex sentences and spared
single-word comprehension and object knowledge met the clin-
ical diagnostic criteria for imaging-supported non-ﬂuent/agram-
matic variant PPA (nfvPPA; Gorno-Tempini et al., 2011). The
mutation carriers without clinical features of FTD (FTD-CDR-
SB of 0 at all study visits) are referred to as ‘non-converters’
(n=35). See Supplementary Table 1 and Supplementary mater-
ial for demographic, neuroimaging, clinical and neuropsycho-
logical data of the converters, and Fig. 1 for converters’
symptom onset within the study time-window.
Study design
The converters were compared to non-converters and non-car-
riers at three time points: baseline, follow-up after 2 and
4 years, presented as:
(i) 4 years before symptom onset: clinical and MRI data were
available in six converters, as two developed symptoms be-
tween baseline and ﬁrst follow-up visit, and therefore no
data 4 years prior to symptom onset were available. Data
were compared to baseline data of non-converters and
non-carriers.
(ii) 2 years before symptom onset: clinical and MRI data were
available for eight converters and compared to data of the 2-
year follow-up of non-converters and non-carriers. Seven of the
eight converters had reliable diffusion tensor imaging (DTI)
data, while one converter (MAPT) was excluded due to insuf-
ﬁcient data quality.
(iii) After symptom onset: clinical and MRI data were available
from eight converters, and were compared to data of the
follow-up after 4 years of non-converters and non-carriers.
DTI data of seven converters were reliable, while one con-
verter (MAPT) was excluded due to insufﬁcient data quality.
Image acquisition and
(pre)processing
On each study visit, we acquired volumetric T1-weighted and
diffusion tensor images on a Philips 3T Achieva MRI scanner
(Philips Medical Systems) using an 8-channel SENSE head coil.
Images were preprocessed by means of standard FMRIB
Software Library (FSL; version 5.0.6) voxel-based
morphometry (VBM) and tract-based spatial statistics (TBSS)
preprocessing tools (http://www.fmrib.ox.ac.uk/fsl). See the
Supplementary material for speciﬁc image acquisition param-
eters and preprocessing pipelines. The resulting images were
fed into whole-brain voxelwise statistics and region of interest
analyses (see below).
Whole-brain voxelwise statistics:
TBSS and VBM
We investigated cross-sectional white matter diffusion (frac-
tional anisotropy) and grey matter volume differences between
converters, non-converters and non-carriers at the three time
points by means of permutation-based testing using 5000 per-
mutations, applying one-way ANCOVAs with age and gender
as covariates. Change over time maps were generated by sub-
tracting the white matter and grey matter maps calculated at
the post-symptom onset visit from the maps calculated at the
4 years before symptom onset visit in FSL. Using TFCE in
Randomise, the signiﬁcance level was set at family-wise
error-corrected P 5 0.05. As the ﬁeld of view of the diffusion
tensor images provided incomplete coverage of the lower brain
areas including the cerebellum, the cerebellum was masked out
from the TBSS analyses. In one of the converters we found a
large (asymptomatic) cerebellar cyst, we therefore performed
the VBM analyses in two steps, ascertaining that this subject
did not signiﬁcantly affect the results in the cerebellum: (i) the
entire group with the cerebellum included in all subjects; and
(ii) the analysis excluding the above-mentioned converter.
Region of interest selection
Based on an extensive literature search into white matter and
grey matter changes in FTD (Supplementary material and
Supplementary Table 2), we selected the following white matter
regions of interest: uncinate fasciculus, superior longitudinal fas-
ciculus, inferior longitudinal fasciculus, inferior fronto-occipital
fasciculus, genu, body and splenium of the corpus callosum,
fornix, cingulum bundle, and forceps minor. The John Hopkins
University 1-mm atlas in FSL was used to parcel the entire white
matter into predeﬁned regions of interest (http://fsl.fmrib.ox.ac.
uk/fsl/fslwiki/Atlases; Mori et al., 2005). Using FSL tools, the
regions of interest were restricted to voxels included in the
mean fractional anisotropy skeleton mask, after which they
were applied to the fractional anisotropy skeleton, giving left
and right fractional anisotropy values per tract for each partici-
pant. The Harvard-Oxford 2-mm structural Atlas in FSL was
applied to each subjects’ native space grey matter segmentation,
after which the mean voxel grey matter partial volume estimation
per region (48 left, 48 right regions of interest) was multiplied
with the total volume of the image (in mm3/1000), giving the
grey matter per region in millilitres. For the grey matter regions
of interest, we selected the following regions: frontal lobe, pre-
frontal cortex, anterior temporal lobe, total temporal lobe, anter-
ior cingulate cortex, total cingulate cortex, and insular cortex.
The total cortical lobes and cingulate were the sum of all regions
belonging to that area. The insula and anterior cingulate cortex
were taken directly from the atlas. The prefrontal region of inter-
est was the sum of the frontal pole, orbitofrontal cortex, and
superior, middle and inferior frontal gyrus. The anterior temporal
region of interest was the sum of the temporal pole and the
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anterior divisions of the superior, middle and inferior temporal
gyrus. All grey matter regions of interest were corrected for head
size by expressing it as a percentage of the total intracranial
volume in ml (%TIV), as automatically calculated in SPM12
(Wellcome Trust Centre for Neuroimaging, UCL, London, UK)
running in MATLAB (version R2013b).
Statistical analysis
Statistical analyses were performed using SPSS Statistics 21.0
(IBM Corp., Armonk, NY) and GraphPad Prism 7 (La Jolla,
California, USA). The signiﬁcance level was set at P5 0.05
(two-tailed) across all comparisons. We compared baseline
demographic data between groups by means of one-way
ANOVA, with Bonferroni post hoc testing. Between-group dif-
ferences in sex were analysed using Pearson 2 tests. We ana-
lysed longitudinal data points of global cognition and
questionnaires using linear mixed models. We investigated
the classiﬁcation abilities of region of interest white matter
integrity and grey matter volume loss to discriminate between
converters, non-converters and non-carriers by determining the
area under the curve with 95% conﬁdence intervals obtained
by receiver operating characteristic analyses, with optimal cut-
off levels at the highest Youden’s index (sensitivity + speciﬁ-
city – 1; Youden, 1950). First, for ease of interpretation, we
standardized all raw fractional anisotropy and grey matter
volumes by converting them into z-scores per time point (i.e.
raw score minus the mean of non-carriers, divided by the
standard deviation of non-carriers). Then, we calculated delta
z-scores between time points per region of interest (after onset
minus 4 years before symptom onset). To assess the perform-
ance of combinations of neuroimaging parameters, we per-
formed logistic regression analyses, taking group (converter
versus non-converter and converter versus non-carrier) as
dependent variable and the delta z-scores as independent vari-
ables. The models were selected with a forward stepwise
method according to the likelihood ratio test and by applying
the standard P-values for variable inclusion (0.05) and exclu-
sion (0.10), with age and gender as covariates. Goodness of ﬁt
was evaluated with the Hosmer-Lemeshow 2 test. Nagelkerke
R2 is reported as measure of effect size. To examine the con-
verters’ within-individual trajectories, we converted the raw
clinical data scores to z-scores (i.e. individual test score
minus the baseline mean of the non-carriers, divided by the
baseline standard deviation of non-carriers) per time point. We
calculated composite z-scores for cognitive domains by calcu-
lating z-scores per test and averaging the z-scores of the indi-
vidual tests per domain (see Jiskoot et al., 2016, 2018a for the
neuropsychological assessment battery).
Data availability
The data that support the ﬁndings of this study are available on
request from the corresponding author. The data are not publicly
available as they contain information that could compromise the
privacy of research participants (e.g. their mutation carriership).
Results
Demographics and clinical data
Demographic and clinical data of converters, non-con-
verters and non-carriers are shown in Table 1. The mean
familial age at symptom onset in converters was lower than
in non-converters and non-carriers (both P= 0.006). After
symptom onset, converters had lower MMSE scores than
non-converters and non-carriers (both P5 0.001) and
Table 1 Demographics and clinical data
Demographic Converters (n = 8) Non-converters (n = 35) Non-carriers (n = 30) P-value
Age at study entry, years 49.5  9.6 50.3  10.2 50.6  10.7 0.966
Sex, female (%) 4 (50) 21 (60) 19 (63.3) 0.790
Education (Verhage)a 6.0  0.6 5.5  1.0 5.4  1.0 0.365
Gene, GRN (%) 3 (37.5) 27 (77.1) 24 (80) 0.050
Onset age family, years 52.4  7.0 59.2  5.5 59.4  4.7 0.005
Years from estimated onset at study entry 5.0  4.7 8.9  8.1 N/A 0.596
Clinical data Years to onset
MMSE 4 29.3  0.8 29.2  1.5 29.4  0.9 0.685
2 29.1  1.1 28.8  1.9 29.4  1.1 0.288
0 26.3  3.3 29.3  1.2 29.4  0.9 50.001
FABb 4 - - - -
2 17.3  0.8 17.5  0.9 17.5  0.8 0.888
0 15.7  1.6 17.1  1.1 16.9  1.4 0.057
BDI 4 1.3  1.6 3.5  4.8 4.0  4.3 0.414
2 3.1  3.9 3.2  4.2 3.7  4.1 0.897
0 9.6  10.5 3.0  6.6 3.5  4.3 0.032
NPI-Qb 4 - - - -
2 0.1  0.4 2.9  13.6 0.7  1.3 0.638
0 13.6  16.4 3.9  12.2 0.8  1.5 0.015
Values indicate: mean  SD. BDI = Beck’s Depression Inventory; FAB = Frontal Assessment Battery; MMSE = Mini-Mental State Examination.
aDutch educational system categorized into levels from 1 = 56 years of primary education to 7 = academic schooling (Verhage et al., 1964).
bData only available on follow-up visits.
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signiﬁcantly more neuropsychiatric features, reﬂected in
higher BDI (P = 0.031 and P = 0.054, respectively) and
NPI-Q (P = 0.075 and P = 0.011, respectively) scores. In lon-
gitudinal analyses, converters showed a signiﬁcant decrease
in MMSE over time (P= 0.002). Changes in global cogni-
tion or neuropsychiatric features did not reach statistical
signiﬁcance in non-converters and non-carriers, although
somewhat higher NPI-Q scores were found in non-con-
verters at 2- and 4-year follow-up.
Cross-sectional whole brain white
matter integrity and grey matter
volume loss
Four years before symptom onset, converters did not show
any differences in fractional anisotropy or grey matter
volume compared to non-converters and non-carriers
[Table 2 and Fig. 2A(i)]. Two years before symptom
onset, converters had lower fractional anisotropy values
Table 2 Whole brain comparisons (TBSS, VBM) between converters, non-converters and non-carriers
WM/GM Cluster Size P MNI coordinates L/R Area (peak voxel)
x y z
Converters versus non-converters
4 years before symptom onset WM - - ns - - - - -
GM - - ns - - - - -
2 years before symptom onset WM 1 21781 0.004 15 42 –12 R IFOF, UF, forceps minor
2 1882 0.023 34 1 –32 R Cingulum
3 144 0.047 48 –36 –4 R SLF
4 66 0.049 –48 –10 22 L SLF
5 19 0.050 –56 0 15 L SLF
GM 1 27122 50.001 10 12 –28 R Orbitofrontal cortex
2 4660 0.004 –40 2 –26 L Planum temporale
After symptom onset WM 1 61066 50.001 35 –8 –37 R ILF
GM 1 88222 50.001 50 –12 –46 R Inferior temporal gyrus
Longitudinal decline WM 1 894 0.047 –3 153 84 n/a gCC
GM 1 18601 0.001 –30 22 2 L Insula
2 6318 0.001 44 –32 –26 R Inferior temporal gyrus
Converters versus non-carriers
4 years before symptom onset WM - - ns - - - - -
GM - - ns - - - - -
2 years before symptom onset WM 1 21781 0.004 15 42 –12 R IFOF, UF, forceps minor
2 1882 0.023 34 1 –32 R Cingulum
3 144 0.047 48 –36 –4 R SLF
4 66 0.049 –48 –10 22 L SLF
5 19 0.050 –56 0 15 L SLF
GM 1 23126 50.001 40 –38 –30 R Fusiform gyrus
2 538 0.021 –16 50 32 L Frontal pole
After symptom onset WM 1 62308 50.001 14 50 –15 R IFOF, UF
GM 1 81558 50.001 42 –10 –48 R Inferior temporal gyrus
2 439 0.030 –14 –62 44 L Precuneus
3 150 0.036 –18 –78 –4 L Lingual gyrus
4 41 0.047 20 –86 –4 R Occipital fusiform gyrus
Longitudinal decline WM 1 914 0.026 –2 153 84 n/a gCC
GM 1 25216 0.001 –44 6 –30 L Temporal pole
2 11300 0.001 46 –32 28 R Inferior temporal gyrus
3 1165 0.014 18 –88 12 R Occipital pole
4 391 0.029 –34 –70 22 L Lateral occipital cortex
5 82 0.046 –20 –90 –4 L Occipital pole
Non-converters versus non-carriers
4 years before symptom onset WM - - ns - - - - -
GM - - ns - - - - -
2 years before symptom onset WM - - ns - - - - -
GM - - ns - - - - -
After symptom onset WM - - ns - - - - -
GM - - ns - - - - -
Longitudinal decline WM - - ns - - - - -
GM - - ns - - - - -
gCC = genu corpus callosum; GM = grey matter; IFOF = inferior fronto-occipital fasciculus; ILF = inferior longitudinal fasciculus; L = left; MNI = Montreal Neurological Institute; n/a =
not applicable; ns = non-significant; R = right; SLF = superior longitudinal fasciculus; TBSS = Tract-Based Spatial Statistics; UF = uncinate fasciculus; VBM = voxel-based morphometry;
WM = white matter. Clusters 450 voxels have been reported. P 5 0.05, FWE-corrected for multiple comparisons.
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in the uncinate fasciculus, superior longitudinal fasciculus,
inferior fronto-occipital fasciculus, inferior longitudinal fas-
ciculus, corpus callosum, forceps minor, cingulum, anterior
thalamic radiation and anterior corona radiata than both
the other two groups [Table 2, Fig. 2A(ii) and B(ii)].
Lower grey matter volumes were found in the bilateral
frontal and temporal lobes, insula and cingulate cortex,
extending to the parietal lobe and cerebellum of converters
compared to non-converters and non-carriers [Table 2 and
Fig. 2A(ii)]. After symptom onset, converters had lower
fractional anisotropy values across all white matter tracts
[Table 2 and Fig. 2A(ii)], and lower grey matter volumes of
large areas covering the frontal and temporal cortices, but
also subcortical areas (e.g. thalamus) and cerebellum, with
relative sparing of the parietal and occipital lobes in com-
parison to non-converters [Table 2 and Fig. 2A(ii)]. The
differences were in similar locations, but more extensive
in comparison to non-carriers [Table 2 and Fig. 2B(ii)].
The results were not affected by the converter with the
cerebellar cyst, as exclusion did not change the above-
mentioned ﬁndings. No signiﬁcant differences in fractional
anisotropy or grey matter volumes were found between non-
converters and non-carriers at any time point (Table 2).
Longitudinal whole brain white
matter integrity and grey matter
volume loss
Converters demonstrated longitudinal decline of fractional
anisotropy in the genu corpus callosum and forceps minor
over time compared to non-converters (Table 2 and
Fig. 3A); this was even more extensive (left uncinate fascic-
ulus, left superior longitudinal fasciculus and posterior
corpus callosum) when compared to non-carriers (Table 2
and Fig. 3A). The longitudinal trajectories of the right un-
cinate fasciculus and genu corpus callosum are shown in
Fig. 4A. Furthermore, converters had signiﬁcant grey
matter volume loss of the prefrontal cortex, cingulate
cortex, insula, temporal poles and inferior temporal gyrus
in comparison to non-converters (Table 2 and Fig. 3B),
again with more extensive grey matter volume loss (most
of the frontal and temporal lobes, extending to the occipital
cortex and cerebellum) compared to non-carriers (Table 2
and Fig. 3B). These results were also not affected by the
converter with the cerebellar cyst, as exclusion did not
change the above-mentioned ﬁndings. There were no sig-
niﬁcant differences in fractional anisotropy or grey matter
volume loss between non-converters and non-carriers
(Table 2).
Within-individual trajectories in
converters
We further assessed the converters’ within-individual pro-
gression of global cognitive (MMSE, FAB), neuropsychi-
atric (NPI-Q), neuropsychological (language, executive
function, social cognition, attention, memory) and neuroi-
maging (frontal and temporal lobe volume) measures
(Fig. 5). Furthermore, a brief description of the clinical dis-
ease trajectories, including the onset of behavioural, neuro-
psychiatric, cognitive and neuroimaging changes can be
found in the Supplementary material. As Figs 4A, 5
and the Supplementary material show, most MAPT con-
verters had a relatively gradual onset of symptoms, re-
ﬂected in slowly progressive clinical features and cognitive
disturbances, but a steep increase of neuropsychiatric
and grey matter volume loss. The GRN converters
Figure 2 Cross-sectional whole brain grey matter volume and white matter integrity differences between converters,
non-converters and non-carriers. Maps illustrate significant differences in white matter integrity (fractional anisotropy; left) and grey matter
volume (right) between (A) converters and non-converters, and (B) between converters and non-carriers at (i) 4 years before onset; (ii) 2 years
before onset; and (iii) at symptom onset. Fractional anisotropy thresholded (P < 0.05) statistical images were thickened using tbss_fill in FSL for
better visibility. Colour bars represent P-values.
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demonstrated more rapid changes in all biomarkers around
symptom onset. With respect to cognition, MAPT con-
verters demonstrated decline in all domains, namely lan-
guage, attention, executive function, social cognition, and
memory, while GRN converters declined most on attention
and executive function (Supplementary Table 1 and Fig. 5).
With respect to grey matter atrophy, visual inspection
showed a disproportional volume loss of the (right) tem-
poral lobes in MAPT converters, and relatively more
volume loss of the (left) frontal lobes in GRN converters
(Fig. 5). Visual inspection of the white matter trajectories
suggested more fractional anisotropy decline in the uncin-
ate fasciculus in MAPT converters than GRN converters,
and more decline in the genu corpus callosum in GRN
converters than MAPT converters (Fig. 4A). As most con-
verters with bvFTD had an underlying MAPT mutation,
similar patterns of decline were found; comparably, all con-
verters with nfvPPA had an underlying GRN mutation, and
therefore showed similar patterns of decline to GRN con-
verters (Figs 4A and 5). A steep increase of neuropsychi-
atric symptoms was noted in most bvFTD converters
(converter 1, 2, 4 and 8), but not in nfvPPA converters
(Supplementary material and Fig. 5).
Classification
Between converters and non-converters, longitudinal de-
cline in the white matter integrity of the right uncinate
fasciculus and genu corpus callosum provided signiﬁcant
classiﬁers (Table 3 and Fig. 4B). Decline in the genu
corpus callosum provided the best ﬁt for classifying
between converters and non-converters (2 = 0.738;
P5 0.001). The model correctly classiﬁed 85.0% of
cases. Between converters and non-carriers, longitudinal de-
cline of the right uncinate fasciculus, genu corpus callosum,
forceps minor, right inferior fronto-occipital fasciculus,
right insula, and left anterior temporal lobe, provided sig-
niﬁcant classiﬁers (Supplementary Table 3 and Fig. 4B).
Decline in the genu corpus callosum and right inferior lon-
gitudinal fasciculus provided the best ﬁt for classifying be-
tween converters and non-carriers (2 = 1.000; P5 0.001).
The model correctly classiﬁed 100% of cases.
Discussion
Our study is the ﬁrst 4-year longitudinal study examining
different neuroimaging modalities in a large cohort of at-
risk participants from families with FTD due to MAPT or
GRN mutations. Eight mutation carriers developed clinical
features of FTD (‘converters’). Cross-sectional analyses
demonstrated extensive loss of white matter integrity and
grey matter volume in converters, present from 2 years
before symptom onset. Longitudinal analyses demonstrated
the largest decline over time in the genu corpus callosum,
uncinate fasciculus, forceps minor, and superior longitu-
dinal fasciculus, as well as the prefrontal and cingulate
cortex, insula, temporal pole and inferior temporal gyrus.
Classiﬁers between converters, non-converters and non-car-
riers were white matter integrity loss of the right uncinate
fasciculus and genu corpus callosum. Decline in the genu
corpus callosum and right inferior longitudinal fasciculus
Figure 3 Longitudinal whole brain grey matter volume and white matter integrity differences between converters,
non-converters and non-carriers. Maps illustrate significant differences in white matter integrity (left) and grey matter volume (right) between
(A) converters and non-converters and (B) between converters and non-carriers. Fractional anisotropy thresholded (P < 0.05) statistical images
were thickened using tbss_fill in FSL for better visibility. Colour bars represent P-values.
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provided the best measures for classifying between con-
verters and non-converters.
Analogous to other cohort studies in familial FTD
(Rohrer et al., 2015), Alzheimer’s disease (Bateman et al.,
2012; Benzinger et al., 2013; Kinnunen et al., 2018), and
Huntington’s disease (Tabrizi et al., 2013; Harrington
et al., 2016), the transition period between presymptomatic
and symptomatic disease stage, the time point of patho-
physiological changes, type of progression and topograph-
ical order of neuroimaging changes, and genotype versus
phenotype-speciﬁc patterns may give signiﬁcant insights
into the exact disease process of FTD; these are addressed
below.
One of the key beneﬁts of our study is the use of actual
onset age in converters. Looking in more detail at symptom
onset, converters with GRN mutations had a more sudden
start of symptoms, while subtle behavioural and cognitive
changes evolved over years in a few MAPT mutation
carriers. Conversion was based on onset of clinical features
of FTD (behavioural and/or language deterioration), signiﬁ-
cant functional decline, and neurocognitive deﬁcits. All
eight converters met the diagnostic criteria for probable
bvFTD (Rascovsky et al., 2011), or imaging-supported
PPA (Gorno-Tempini et al., 2011), as they had frontal
and/or temporal atrophy consistent with patterns described
in early-stage symptomatic MAPT- and GRN-related FTD
(Whitwell et al., 2009b, 2012; Rohrer et al., 2010; Cash
et al., 2018). Although the present study does not include
C9orf72-related FTD, it is important to recognize that
symptomatic mutation carriers initially can have relatively
normal structural imaging (Khan et al., 2012; Devenney
et al., 2015) or atrophy patterns are less pronounced
than in sporadic bvFTD (Devenney et al., 2014); therefore
using frontal and/or temporal MRI abnormalities as core
criteria in deﬁning clinical conversion could miss a propor-
tion of mutation carriers if generalized to a cohort
Figure 4 Longitudinal trajectories and classification accuracy of white matter integrity decline from the presymptomatic to
symptomatic phase. (A) Longitudinal trajectories of white matter integrity (fractional anisotropy, FA) loss (z-score) in the right uncinate
fasciculus (UF; top row) and genu of the corpus callosum (gCC; bottom row) in converters, non-converters and non-carriers. Open circles represent
GRN converters; filled circles represent MAPT converters. Note that data points for two converters (one MAPT, one GRN) are missing at 4 years
before symptom onset, as they converted between baseline and first follow-up, and therefore do not have the 4 years before symptom onset scan
available. DTI data were of unsatisfactory quality for one (MAPT) converter 4 years before symptom onset (only uncinate fasciculus), and another
(MAPT) converter 2 years before symptom onset (both uncinate fasciculus and genu of the corpus callosum) and were therefore excluded. Data
were unavailable at symptom onset for one converter (MAPT) as the scan session was terminated prematurely. (B) Classification between
converters, non-converters and non-carriers using the z-score delta fractional anisotropy of the right uncinate fasciculus (top) and the genu of the
corpus callosum (bottom). The dashed line represents the optimal cut-off to separate converters and non-converters (uncinate fasciculus: delta
fractional anisotropy = –0.51; sensitivity = 100%, specificity = 62.5%; genu of the corpus callosum: delta fractional anisotropy = –0.85; sensitiv-
ity = 100%, specificity = 81.3%). The optimal cut-off between converters and non-carriers (not shown) is –0.39 (sensitivity = 100%, specifi-
city = 69.6%) and –0.87 (sensitivity = 100%, specificity = 91.3%) for the uncinate fasciculus and genu of the corpus callosum, respectively. Open
circles represent GRN converters; filled circles represent MAPT converters. Note that deltas for two converters (one MAPT, one GRN) are missing,
as they converted between baseline and first follow-up, and therefore do not have the 4 years before symptom onset scan available. DTI data of
the uncinate fasciculus for one (MAPT) converter were excluded due to unsatisfactory quality.
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including C9orf72. The exact timing of conversion was dif-
ﬁcult to pinpoint due to a transitional stage of subtle be-
havioural or language impairment (Gorno-Tempini et al.,
2011; Rascovsky et al., 2011), in line with the ‘question-
ably/mildly symptomatic mutation carriers’ described by
Kinnunen et al. (2018). Analogous to the mild cognitive
impairment (MCI) phase in Alzheimer’s disease, several
terms have been opted for this time period in FTD, such
as ‘pre-bvFTD’ (Borroni et al., 2015), ‘prodromal fronto-
temporal dementia [FTD]’ (Hallam et al., 2007), ‘fronto-
temporal MCI’ (De Mendonc¸a et al., 2004) and the more
broadly deﬁned ‘Mild Behavioural Impairment’ (Taragano
et al., 2009). However, they do not capture the entire range
of possible clinical features in presymptomatic familial
Figure 5 Within-individual trajectories of clinical and neuroimaging changes in converters. Raw data for each marker were first
converted to z-scores by standardization to the baseline data of non-carriers. Each subplot (labelled with the converters number) presents the
longitudinal global cognitive, neuropsychological and grey matter neuroimaging values (z-scores, y-axis) from 4 years to symptom onset to
symptom onset (x-axis). The grey matter volumes of the most affected hemisphere are displayed (i.e. right side in converters with bvFTD, left side
in all converters with nfvPPA). Coloured asterisks denote significant longitudinal decline (51 SD) over time. FAB = Frontal Assessment Battery;
MMSE = Mini-Mental State Examination.
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FTD, including early stage PPA. This emphasizes the need
for additional clinical, neuroimaging, or ﬂuid biomarkers.
As a ﬁrst step, incorporating neuropsychiatric measures
into the deﬁnition of the transitional period of FTD could
be considered, as subtle neuropsychiatric changes were
found in presymptomatic mutation carriers in this and in
previous studies (Rohrer et al., 2015; Cheran et al., 2018).
The most interesting ﬁndings of our study are the longi-
tudinal changes in grey and white matter integrity 2 years
before actual symptom onset, suggesting a speciﬁc ‘change-
point’ when approaching symptom onset. A similar pattern
was demonstrated regarding neuropsychological bio-
markers in the same cohort (Jiskoot et al., 2018a), with a
sudden onset of cognitive decline in e.g. language, executive
function, social cognition and memory from 2 years before
symptom onset. Previous studies using estimated years to
onset as a proxy demonstrated similar changes in grey
matter volume (Rohrer et al., 2015), white matter integrity
(Jiskoot et al., 2018b) and cognition (Jiskoot et al., 2016),
albeit earlier in the presymptomatic period, i.e. 5–10 years
before estimated symptom onset. The discrepancy between
the ﬁndings in our study and those in the larger GENFI
study may be explained by the smaller and different sam-
ples (e.g. inclusion of C9orf72 mutation carriers, all muta-
tion carriers combined in one group), differences in analysis
method (mixed-effects models versus ANCOVAs on
changes over time maps, percentage of total intracranial
volume versus corrected absolute volume), and the use of
estimated years to onset versus actual symptom onset.
Furthermore, when using cross-sectional data, inferences
depend on the assumption that biomarker trajectories are
similar across patients (Benzinger et al., 2013), while in this
study we were able to show that within-individual trajec-
tories can differ. An interesting issue is the type of change
(e.g. stepped change, linear) and rate of progression (e.g.
gradual, accelerated) occurring after this change-point, and
a study with a larger cohort of converters with longer
follow-up will certainly shed more light on this matter.
The present ﬁndings of a relatively rapid/abrupt trajectory
of white and grey matter changes seems to be in contrast
with that seen in familial Alzheimer’s disease (Bateman
et al., 2012; Benzinger et al., 2013). However, studies in
familial Alzheimer’s disease also show accelerated decline in
the proximity of symptom onset (Hassenstab et al., 2016;
Kinnunen et al., 2018), with disease rates being at least
3.6 times higher after the change-point (Kinnunen et al.,
2018). FTD, having shorter survival and faster rates of
decline than Alzheimer’s disease (Rascovsky et al., 2005),
could have an even faster rate of disease progression after
the change-point.
The spatial distribution of grey matter and white matter
changes 2 years before onset corresponds with signiﬁcant
loss of both white matter integrity and grey matter
volume over time in symptomatic FTD (Frings et al.,
2014; Lam et al., 2014; Mahoney et al., 2014; Elahi
et al., 2017). The lower white matter integrity of the un-
cinate fasciculus in converters 2 years before symptom
onset conﬁrmed this tract as the molecularly most vulner-
able hub, as also found in previous studies (Borroni et al.,
2008; Dopper et al., 2014; Jiskoot et al., 2018b). The in-
volvement of several other tracts after symptom onset in
our study supports the hypothesis of a network-led frame-
work, in which neurodegeneration propagates along large-
scale distributed white matter networks with disease
progression (Seeley et al., 2009). The spatial patterns of
white matter integrity and grey matter volume loss revealed
a strong co-localization, conﬁrming some previous studies
(Acosta-Cabronero et al., 2011; Hornberger et al., 2011),
but contrasting with others (Agosta et al., 2010, 2012;
Mahoney et al., 2013, 2014; Schwindt et al., 2013;
Zhang et al., 2013). Although cross-sectional in nature,
the cascade of presymptomatic grey matter changes found
in the GENFI cohort (Rohrer et al., 2015) was similar to
the longitudinal patterns found in this study, with the at-
rophy spreading from the insula, temporal and frontal cor-
tices to the cingulate, parietal and occipital cortices with
approaching estimated symptom onset.
Prior studies have suggested that white matter abnormal-
ities occur earlier and tend to exceed the grey matter atro-
phy (Agosta et al., 2012; Rohrer and Rosen, 2013; Frings
et al., 2014; Lam et al., 2014). We found relatively simul-
taneous onset of changes in white matter integrity and grey
matter volume loss. The small number of converters did not
allow us to detect a robust sequential order of grey and
white matter involvement or between speciﬁc cortical re-
gions, while more extensive progression of white matter
pathology than grey matter abnormalities were found in
longitudinal studies in the symptomatic stage (Frings
et al., 2014; Lam et al., 2014). In our study, the progres-
sion of grey matter atrophy seems visually larger than the
white matter integrity loss. Potentially, this does not occur
initially in the presymptomatic stage, but later on in the
disease process (Lam et al., 2014). Our ﬁndings are in con-
trast with the more temporal order found in familial
Alzheimer’s disease, reﬂected in elevated amyloid
[Pittsburgh compound B (PiB)] PET 15 years before esti-
mated onset, followed by reduced glucose metabolism
[ﬂuorodeoxyglucose (FDG)-PET] 10 years before estimated
onset, and cortical thinning 5 years before estimated onset
(Benzinger et al., 2013). As FDG-PET scanning has only
been carried out in a small series of presymptomatic muta-
tion carriers (Caroppo et al., 2015), the use of FDG-PET in
a larger cohort will deﬁnitively give more insights into the
temporal sequence of pathophysiological changes.
Analogous to PiB-PET scanning in Alzheimer’s disease,
the future availability of an optimal tau PET tracer in pre-
symptomatic carriers with MAPT mutations will also give
more information about the topographical and spatial
spreading of tau pathology and its trajectory relative to
grey matter atrophy and white matter integrity loss
(Smith et al., 2016; Ono et al., 2017).
Regarding genotype-speciﬁc patterns of neuroimaging
biomarkers, the uncinate fasciculus in MAPT converters
tended to show the most decline in white matter integrity,
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and GRN converters showed the most decline in the genu
corpus callosum, although the numbers in both groups
were too low to perform statistical analyses in order to
draw ﬁrmer conclusions. These ﬁndings are in line with
reported white matter atrophy of the uncinate fasciculus
in MAPT-associated FTD, and white matter atrophy of
the corpus callosum in GRN-associated FTD (Rohrer
et al., 2010). Most of the MAPT converters in our study
presented with bvFTD, which could explain the prominent
involvement of the uncinate fasciculus, as reported earlier
by Rohrer et al. (2010). Its role in both the language pro-
cessing pathway (Grossman et al., 2004) and its anatomical
connections to the limbic system in the temporal lobe
(Olson et al., 2015) explains the strong connection between
early damage to the uncinate fasciculus and the clinical
phenotypes of MAPT and bvFTD, characterized by severe
semantic and behavioural disturbances. With respect to
grey matter atrophy, visual inspection showed more tem-
poral volume loss in MAPT converters and frontal volume
loss in GRN converters, in line with previous studies into
both presymptomatic (Rohrer et al., 2015) and symptom-
atic familial FTD (Whitwell et al., 2009b, 2012; Cash et al.,
2018). Most of the GRN converters in our study presented
with nfvPPA, in which the speech production impairments
have been associated with prominent atrophy of the pre-
motor cortex and the inferior frontal lobes (Rohrer et al.,
2013). With respect to disease progression, most converters
with MAPT mutations had a slower progressive onset in
clinical features, cognition, and grey matter atrophy and
white matter integrity loss, indicating a more gradual dis-
ease progression. In contrast, all converters with GRN mu-
tations had more rapid changes in these biomarkers around
symptom onset, in line with a faster disease progression
(Whitwell et al., 2015) and atrophy occurring nearer to
symptom onset (Cash et al., 2018). Our results suggest
variable disease trajectories between genetic mutation
groups as well as within different genetic mutations, yet it
remains to be elucidated whether the structural changes are
solely phenotype-speciﬁc (bvFTD versus nfvPPA) changes,
or whether they will follow genotypic patterns as well.
Table 3 Diagnostic performance of white matter integrity and grey matter volume loss between converters and
non-converters
L/R AUC (95% CI) P Optimal cut-off Sensitivity Specificity
White matter tracts
UF R 0.83 (0.62–1.00) 0.047 –0.51 100% 62.5%
L 0.81 (0.61–1.00) 0.059 - - -
SLF R 0.72 (0.50–0.93) 0.186 - - -
L 0.64 (0.31–0.97) 0.395 - - -
gCC n/a 0.91 (0.86–1.00) 0.014 –0.85 100% 81.3%
bCC n/a 0.59 (0.26–0.93) 0.571 - - -
sCC n/a 0.72 (0.46–0.97) 0.186 - - -
Fornix n/a 0.80 (0.54–1.00) 0.073 - - -
Forceps minor n/a 0.73 (0.47–0.99) 0.156 - - -
Cingulum bundle n/a 0.72 (0.36–1.00) 0.186 - - -
IFOF R 0.77 (0.54–0.99) 0.108 - - -
L 0.67 (0.41–0.94) 0.299 - - -
ILF R 0.64 (0.37–0.91) 0.395 - - -
L 0.63 (0.28–0.97) 0.450 - - -
Grey matter areas
Frontal lobe R 0.53 (0.22–0.84) 0.832 - - -
L 0.66 (0.30–1.00) 0.235 - - -
Prefrontal cortex R 0.52 (0.20–0.83) 0.899 - - -
L 0.66 (0.31–1.00) 0.218 - - -
Temporal lobe R 0.69 (0.35–1.00) 0.137 - - -
L 0.61 (0.33–0.89) 0.396 - - -
ATL R 0.51 (0.25–0.78) 0.932 - - -
L 0.76 (0.47–1.00) 0.051 - - -
Insula R 0.66 (0.38–0.94) 0.218 - - -
L 0.60 (0.34–0.86) 0.445 - - -
Cingulate cortex R 0.61 (0.31–0.91) 0.396 - - -
L 0.78 (0.50–1.00) 0.034 –0.29 83.3% 86.7%
ACC R 0.74 (0.37–0.92) 0.270 - - -
L 0.65 (0.36–0.94) 0.252 - - -
ACC = anterior cingulate cortex; ATL = anterior temporal lobe; AUC = area under the curve; bCC = body corpus callosum; gCC = genu corpus callosum; IFOF = inferior fronto-
occipital fasciculus; ILF = inferior longitudinal fasciculus; L = left; n/a = not applicable; R = right; sCC = splenium corpus callosum; SLF = superior longitudinal fasciculus; UF = uncinate
fasciculus. White matter tract values represent fractional anisotropy, ranging between 0 and 1. Grey matter area values are expressed in millilitres, corrected for total intracranial
volume. The optimal cut-off level was determined by the highest Youden’s index (i.e. sensitivity + specificity – 1) (Youden, 1950). Significant P-values are given in bold.
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A larger cohort with more converters will provide us with
more information on this matter, as—in contrast to amyl-
oid-b in CSF and PIB-PET scans in Alzheimer’s disease—
there is a lack of pathophysiological-speciﬁc biomarkers for
FTD.
The predictive value of changes in the uncinate fasciculus,
genu corpus callosum and left cingulate cortex for conver-
sion in the following 2 years is an important and novel
ﬁnding, as multimodal studies into FTD are scarce
(Zhang et al., 2011). The ﬁnding of the genu corpus callo-
sum as a signiﬁcant discriminator between converters and
non-converters is in line with the hypothesis of FTD as a
network disease, in which loss of speciﬁc white matter
tracts connecting grey matter areas results in large network
failure. Studies into frontotemporal and Alzheimer’s disease
have demonstrated both unimodal white matter and grey
matter volume loss as being signiﬁcant discriminators be-
tween both conditions (albeit weaker for grey matter than
white matter), but the optimal classiﬁcation (87% sensitiv-
ity, 83% speciﬁcity) was achieved using a combination of
techniques (McMillan et al., 2012). Furthermore, Mo¨ller
et al. (2015) showed that white matter integrity measures
added complementary information to grey matter atrophy
measures in FTD. It would be valuable for future studies to
replicate the present classiﬁcation ﬁndings, preferably with
different and/or more neuroimaging techniques (e.g. resting
state functional MRI, arterial spin labelling) or other stat-
istical algorithms (e.g. support vector machines, machine
learning techniques) to determine which combination of
approaches could achieve the highest classiﬁcation accuracy
for conversion to the symptomatic disease stage.
With upcoming clinical trials, ongoing studies are inves-
tigating the potential of longitudinal MRI as sensitive dis-
ease biomarkers. These interventions should ideally be
applied in the presymptomatic stage (Meeter et al., 2017).
For both white matter integrity and grey matter volume
loss present at 2 years prior to symptom onset, and increas-
ing pathology when moving into the symptomatic stage,
multimodal neuroimaging has proven its value as a disease
staging and tracking biomarker. Longitudinal DTI changes
in the genu corpus callosum as the strongest predictor for
conversion makes it a potential neuroimaging biomarker
for tracking disease progression in clinical trials, particu-
larly since this is the white matter tract most consistently
found across all clinical FTD syndromes (Elahi et al.,
2017). Interestingly, the white matter integrity loss between
4 and 2 years before symptom onset seems to parallel the
steep increase in neuroﬁlament light chain levels found in
converters in our previous study (Meeter et al., 2016).
Future research should focus on the association between
DTI parameters and neuroﬁlament light chain levels in a
larger sample, as they could serve as potential biomarkers
for disease staging, the prediction of underlying pathology,
and monitoring of treatment response in future therapeutic
trials. Moreover, investigating the white matter tract
abnormalities underlying neuropsychiatric features in con-
version to the symptomatic stage would be an informative
next step, as recent research demonstrated distinct spatial
distributions of white matter pathology to be associated
with speciﬁc behavioural symptoms across the major clin-
ical FTD syndromes (Lansdall et al., 2018).
The key strength of our study is our longitudinal design,
spanning a 4-year follow-up period of tracking at-risk par-
ticipants from both MAPT and GRN families. The non-
carriers from the same families were an ideal control
group, as they had the same genetic and social background.
Second, we used the true onset instead of estimated symp-
tom onset. Third, all subjects underwent DTI imaging on
the same scanner with the same sequencing parameters in a
4-year follow-up period. A drawback is the relatively small
sample size and the clinical and pathological heterogeneity
with respect to statistical power; this warrants replication
in larger longitudinal cohorts with more converters, includ-
ing C9orf72 repeat expansion carriers. Although our
cohort also involves participants from C9orf72 families,
study inclusion started in 2014; therefore no 5-year
follow-up data are available yet. In the current study, we
only described changes in fractional anisotropy, being the
most sensitive parameter in the presymptomatic phase and
the most pronounced measure with disease progression
(Acosta-Cabronero et al., 2012; Dopper et al., 2014; Lam
et al., 2014). However, to interpret the exact neuropatho-
logical processes underlying the DTI changes, future studies
should also include other diffusivity measures. Further, DTI
scan-rescan reliability in neurodegeneration has scarcely
been studied, and can be potentially hampered by its un-
equal distribution throughout different brain regions (i.e.
highly anisotropic white matter tracts have lower within-
subject variability) and higher susceptibility to partial
volume effects in smaller tracts (Cole et al., 2014).
Finally, the DTI ﬁeld-of-view in the present study was too
small to include the lower white matter tracts in our ana-
lyses, although this would have been interesting considering
recent ﬁndings of corticospinal tract degeneration in both
bvFTD and nfvPPA (Omer et al., 2017).
Conclusion
Our longitudinal study demonstrates the presence of
presymptomatic structural neuroimaging changes in FTD
mutation carriers, starting 2 years before onset, with pre-
dominant frontotemporal pathology spreading towards and
into symptom onset. Presymptomatic decline of white
matter integrity of the uncinate fasciculus and genu
corpus callosum, and grey matter volume loss of the left
cingulate cortex, are consistent predictors of symptom
onset in converters. Our results conﬁrm the presence of a
presymptomatic neuroimaging stage of familial FTD, and
highlight the potential value of longitudinal multimodal
structural MRI as a sensitive prognostic and diagnostic
biomarker for presymptomatic to early symptomatic famil-
ial FTD.
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